Live Feed

HOUSTON, Oct. 19, 2026 /PRNewswire/ -- Nutex Health, Inc. (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 28 state-of-the-art micro hospitals and hospital outpatient departments in 12 states and primary care-centric, risk-bearing physician networks, today announced that it plans to file its Form 10-Q for the third fiscal quarter ended Sept. 30, 2026, on Thursday, Nov. 5, 2026, after the market close. The Company will also issue a corresponding press release summarizing financial results on the same day. Nutex Health will host its earnings conference call on Friday, Nov. 6, 2026, at 9:30 a.m. CT to discuss the Company's financial performance and provide a bu

More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16 VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy​ Takeda ((TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (U

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 studyIn key secondary outcomes, 71.2% of patients who responded to Omvoh induction achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission at one year without surgeryINDIANAPOLIS, Oct. 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive late-breaking one-year results from the Phase 3 SHINE-2 st

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at Week 12, the primary endpoint. The treatment difference between ABBV-466 and the monotherapy groups further increased at Week 241Gene expression analysis showed that ABBV-466 treated Crohn's disease patients experienced intestinal tissue repair and barrier restoration by Week 12, with tissue remodeling and metabolic changes reported at Week 241The results will be presented as a late-breaker at the 2026 Annual United European Gastroenterology Week CongressNORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today anno

BEIJING, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Niu Technologies ("NIU" or "the Company") (NASDAQ:NIU), the world’s leading provider of smart urban mobility solutions, today announced that it will report its financial results for the third quarter 2026 before the U.S. market opens on Monday, November 16, 2026. The corporate presentation and financial spreadsheets will be posted on NIU’s investor relations website at:https://ir.niu.com/financial-information/quarterly-results The Company will host an earnings conference call on Monday, November 16, 2026 at 8:00 AM U.S. Eastern Time (9:00 PM Beijing/Hong Kong Time) to discuss the financial and business results. To join via phone, participants n

LONDON, Oct. 19, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE:LAZ) today announced the appointment of David Krap as Managing Director and Co-Head of European Consumer, Retail & Leisure.David brings over two decades of consumer-focused M&A advisory experience, with a particular focus on food and beverage, home and personal care, and select consumer health categories. He joins Lazard from J.P. Morgan, where he served as Managing Director and Co-Head of Consumer & Retail EMEA. Previously, he held senior roles at Credit Suisse, Centerview Partners, and UBS. David holds an honors degree from the European Business School London and is fluent in German and Spanish.Based in London, David will join Lazard

LONDON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Flight prices to selected destinations from the UK have fallen for Christmas and New Year travel, with average return flights down up to 39% compared to last year, according to travel search engine KAYAK’s Christmas Travel Check-in 2026. US destinations lead KAYAK’s flight price drop rankings with average returns from the UK to Atlanta down 39% year-on-year, followed by Washington DC (-27%) and Los Angeles (-20%). Select Caribbean fares are also down, including Kingston (-21%) and Montego Bay (-18%). Which destinations have the biggest flight price drops? DestinationsAvg. Flight Price 2026Change in Price vs. 2025Atlanta, US£587-39%Washington, D.C

Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 CongressData supplements unprecedented two-year data from the trial including a 75% Objective Response Rate with 25% of patients obtaining a complete responseThis new clinical and new immune data will be presented at a poster session on October 24, 2026, followed by a webinar on October 29, 2026, providing further insights into the findings COPENHAGEN, Denmark, October 19, 2026 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, announces new three-year clinical outcome data for p

HAIFA, Israel, Oct. 19, 2026 /PRNewswire/ -- Elbit Systems Ltd. (NASDAQ:ESLT) (TASE: ESLT) ("Elbit Systems" or the "Company") announced today that it was awarded a contract valued at approximately $235 million to supply EXTRA-MR (Medium Range) rockets and Precise & Universal Launching System (PULS™) rocket artillery systems to a European customer, under a government-to-government (G-to-G) agreement between the Israel Ministry of Defense and the customer country's Ministry of Defense. The contract will be performed over a period of three years. Under the contract, Elbit Systems will supply the medium-range variant of the Company

High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a potential first-in-class precision medicine for an estimated 1.5+ million patients in the U.S. with moderate-to-severe TNFR1-mediated dry eye disease (DED)1-4, addressing a critical unmet need in a historically heterogeneous indication. Key Milestone on Track: Topline data from this first-ever genotype-guided registrational trial in DED are anticipated around year-end 2026 ZUG, Switzerland, October 19, 2026 -- Oculis Holding AG (NASDAQ:OCS) (

Collaboration establishes a framework for a dedicated U.S. source of astatine-211 (211At), a scarce, next-generation alpha-emitting isotope with significant potential in targeted alpha therapy (TAT).Secures long-term, priority isotope access for Telix's alpha therapy pipeline, including its TLX102-Tx candidate for glioblastoma and leptomeningeal disease, while also supporting third-party academic and industry programs.First IBA alpha-beam cyclotron to be installed and operated at Telix's RLS Radiopharmacies site near Philadelphia, PA.Leverages Telix's vertically integrated U.S. manufacturing and distribution platform, with a framework providing for the parties to evaluate additional installa

BW LPG Limited ("BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker code: "BWLP") today provides an update on its Product Services’ ("BW Product Services") Q3 2026 segment performance. Q3 2026 highlights: Gross trading result: US$164 million This includes: Realised trading result of US$146 million Positive unrealised mark-to-market movement of US$18 million Net profit after general and administrative expenses and income taxes: US$118 million Average Value-At-Risk (VaR): US$18 million The trading result will form part of the BW LPG Q3 2026 results, which will be released on 24 November 2026 Performance overview: For the quarter ended 30 September

Press release – No. 21 / 2026 Zealand Pharma announces positive topline results from the multiple ascending dose part of Phase 1 trial with Kv1.3 ion channel blocker ZP9830 ZP9830 is a novel Kv1.3 ion channel blocker with pipeline-in-a-product opportunity across a broad range of cell-mediated autoimmune diseases Multiple doses of ZP9830 were well tolerated with no serious or severe adverse events or dose-limiting safety findingsDevelopment program is progressing rapidly with a Phase 1b trial in people with plaque psoriasis recently initiated, and a Phase 2 trial in an additional autoimmune disease planned for initiation in H1 2027 Copenhagen, Denmark, October 19, 2026 – Zealand Pharma A/

SALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Red Cat Holdings, Inc. (NASDAQ:RCAT) ("Red Cat" or the "Company"), a U.S.-based provider of advanced all-domain drone and robotic solutions for defense and national security, today announced a proposed voluntary public purchase offer by Red Cat to acquire all outstanding shares of Steyr Motors AG ("Steyr Motors"), one of the world’s leading companies in the field of customized engines for mission-critical defense and civil applications, for EUR 39.00 per share in cash. The proposed transaction is supported by the Steyr Motors’ anchor shareholder B&C Group and represents a strategic investment in Steyr Motors and Austrian production capabil

Quantum Application Forum, 3 November 2026, gives executives a practical view of where quantum can create commercial value Summary: Real-world quantum use cases: One-day forum on quantum applications for business and public sector priorities in financial services, healthcare, pharmaceuticals, materials science, energy and telecommunications A peer forum for business leaders: Executives from leading organizations will compare approaches to shared challenges, including enterprise readiness, technology roadmaps and investment decisions, as quantum converges with next-generation IT and AI infrastructure Infleqtion (NYSE:INFQ), a global leader in quantum computing and quantum sensing

In the news release, AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio, issued 18-Oct-2026 by AbbVie over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows:AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combi

On October 26, FFR will hold its listing ceremony and first Investor Day at the Nasdaq Tower in New York, where management will share more about FFR's strategy and business plans, with more details to follow soon.Two new EAI Devices launched including FF Nova—America's first entry-level EAI humanoid robot under $2,500, and the second is Nova Mini, a humanoid robot for foundational Physical AI education, priced at $299, with the accompanying curriculum at $499.FF EAI launched two new education and developer training initiatives, the Physical AI Spark Program Curriculum and the Nova Reinforcement Learning Developer Program, while also opening enrollment for its developer community to help expa

On October 26, FFR will hold its listing ceremony and first Investor Day at the Nasdaq Tower in New York, where the management team will share more about its strategy and business plans, more details to follow soon. Two new EAI Devices launched including FF Nova—America’s first entry-level EAI humanoid robot under $2,500, and the second is Nova Mini, a humanoid robot for foundational Physical AI education, priced at $299, with the accompanying curriculum at $499. FF EAI launched two new education and developer training initiatives, the Physical AI Spark Program Curriculum and the Nova Reinforcement Learning Developer Program, while also opening enrollment for its developer community

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse patient needs through next-generation ADCs, combination approaches and precision medicineAbbVie's largest ESMO presence to date highlights longer-term survival data, combination and biomarker findings from multiple assets across various stages of developmentPresentations across investigational and approved medicines to feature Temab-A (telisotuzumab adizutecan), ABBV-706, ABBV-969, ABBV-1480 (RC148), alveltamig, Emrelis™ (telisotuzumab vedotin-tllv) and Elahere®(mirvetuximab soravtansine-gynx)NORTH CHICAGO, Ill., Oct. 1

Median overall survival of 15.8 months in Cyclin E1-positive platinum-resistant ovarian cancer patients treated with azenosertib monotherapy Data to be presented as a rapid oral presentation at ESMO Congress 2026 on October 23, 2026 SAN DIEGO, Oct. 18, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that overall survival (OS) data from an interim analysis of the DENALI Part 1b study (GOG-3066) have been published in the abstract for the upcoming rapid oral presentatio